Evaluation of the efficacy of afoxolaner against two European dog tick species: Dermacentor reticulatus and Ixodes ricinus
Merial SAS, 29 Av Tony Garnier, 69007 Lyon, France; ClinVet International, Universitas 9301, Bloemfontein, Free State, South Africa; Merial Limited, 3239 Satellite Boulevard, Duluth, GA 30096, United States
The acaricidal efficacy of a novel oral formulation of afoxolaner (NEXGARD®, Merial) against two European tick species was assessed in dogs experimentally infested with Ixodes ricinus and Dermacentor reticulatus. Three studies, each characterized by a negative controlled randomized block design, were conducted with a total of 52 beagle or mongrel dogs of both sexes. Starting 2 days before treatment, each dog was infested weekly with approximately 50 ticks. The number of live ticks was counted at 48h post-treatment (Day 2) as well as 48h following each infestation on Days 9, 16, 23, and 30. Afoxolaner, administered at an average dose of 2.7mg/kg bodyweight (range 2.5-2.9mg/kg), rapidly eliminated the pre-existing tick infestations with over 99% acaricidal efficacy and controlled the weekly re-infestations for up to 30 days post treatment with over 96% efficacy on both tick species. Afoxolaner provides excellent acaricidal efficacy against these two major European tick species using the oral route of administration. © 2014 The Authors.
afoxolaner; nexgard; unclassified drug; acaricidal activity; animal experiment; article; beagle; controlled study; Dermacentor reticulatus; drug activity; drug efficacy; drug formulation; experimental infection; female; Ixodes ricinus; male; mongrel dog; nonhuman; parasite clearance; randomized controlled trial; tick infestation; Canis familiaris; Dermacentor reticulatus; Ixodes ricinus; Ixodida; Afoxolaner; Dermacentor reticulatus; Dog; Ixodes ricinus; Tick; Acaricides; Animals; Dermacentor; Dog Diseases; Dogs; Female; Isoxazoles; Ixodes; Male; Naphthalenes; Parasite Load; Random Allocation; Tick Infestations; Treatment Outcome